Awaiting development: Guidance and quality standards

Showing 131 to 140 of 322

Guidance and quality standards awaiting development
Title	Type
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]	Technology appraisal guidance
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]	Technology appraisal guidance
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Infant, children and young people's experience of health care	Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage	Interventional procedures guidance
Intraocular lenses for cataract surgery	Health technology evaluation